ieramilimab ieramilimab ieramilimab (development code lag525) is a monoclonal antibody being developed by novartis for the treatment of cancer. the antibody targets the immune checkpoint lag-3, which is expressed on t cells and tends to down-regulate an immune response. in a june 2015 presentation novartis management indicated that 'dosing is imminent' for the first clinical trials of lag525. ieramilimabmonoclonal antibodytype?clinical dataother nameslag525identifierscas number2137049-37-5uniioi8p0sfd4rkeggd12156 ieramilimab's first clinical trial is a phase i in patients with various solid tumors, in combination with spartalizumab (pdr001), an anti-pd-1 monoclonal antibody has been completed. recruiting for a phase 2 study in combination with spartalizumab for the treatment of metastatic melanoma is underway.